NCT04895397

Brief Summary

In PECSII or modified PECSI block, local anesthetic (LA) is injected between pectoralis major muscle (PMm) and pectoralis minor muscle (Pmm) to block lateral and medial pectoral nerves and between pectoralis minor muscle (Pmm) and serratus anterior muscle in the anterior axillary line to block the intercostal nerves II-VI (Blanco et al., 2012). In Serratus anterior plane block (SAPB) local anesthetic (LA) is injected above the serratus muscle (between latissmus dorsi muscle and serratus muscle) or below the serratus muscle (between serratus muscle and 4th rib) in the mid-axillary line to block the intercostal nerves II-VI and spares the pectoral nerves (Blanco et al., 2013).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable breast-cancer

Timeline
Completed

Started May 2021

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 24, 2021

Completed
26 days until next milestone

First Posted

Study publicly available on registry

May 20, 2021

Completed
Same day until next milestone

Study Start

First participant enrolled

May 20, 2021

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 20, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 20, 2023

Completed
Last Updated

May 20, 2021

Status Verified

May 1, 2021

Enrollment Period

2.1 years

First QC Date

April 24, 2021

Last Update Submit

May 19, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • assess analgesic effect of nerve block

    We assess the analgesic effect by VAS ( visual analogue scale )

    24hour post-operative

Study Arms (2)

Group A: (30 patients)

ACTIVE COMPARATOR

modified pectoral nerve block will be done.

Device: ultrasound guided Nerve Block procedure

Group B: (30 patients)

ACTIVE COMPARATOR

serratus plane block will be done.

Device: ultrasound guided Nerve Block procedure

Interventions

In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally. the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected. the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected. Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane.

Group A: (30 patients)Group B: (30 patients)

Eligibility Criteria

Age20 Years - 60 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Breast cancer surgery.
  • Age 20 to 60 years.
  • Female patients.
  • At least 24 hours post-operative hospital admission.
  • ASA (American society of anesthesiologist) physical status classification system І to Ш.

You may not qualify if:

  • Morbid obesity (body mass index \> 40).
  • Impossibility of anatomical structures identification by ultrasound in a satisfactory way (there can be no distinction in the interfacial plan between serratus and pectoral muscle).
  • Opioids treatment before surgery or substance abuse.
  • Sepsis and/or infection at the puncture site.
  • Hemostasis disorders.
  • Allergy to any of the drugs used in the study.
  • Less than 24 hours postoperative hospital admission.
  • Inability to communicate with the patient.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • mohammed hussein, lecturer

    Sohag University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

mohammed hussein, lecturer

CONTACT

mohamed hussein, lecturer

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Group A: (30 patients) modified pectoral nerve block will be done. Group B: (30 patients) serratus plane block will be done.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

April 24, 2021

First Posted

May 20, 2021

Study Start

May 20, 2021

Primary Completion

June 20, 2023

Study Completion

August 20, 2023

Last Updated

May 20, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing
Will not share